Literature DB >> 19276348

Impaired turnover of prolactin receptor contributes to transformation of human breast cells.

Alexandr Plotnikov1, Bentley Varghese, Thai H Tran, Chengbao Liu, Hallgeir Rui, Serge Y Fuchs.   

Abstract

Signaling by polypeptide hormone prolactin (PRL) is mediated by its cognate receptor (PRLr). PRLr is commonly stabilized in human breast cancer due to decreased phosphorylation of residue Ser349, which when phosphorylated recruits the betaTrcp E3 ubiquitin ligase and facilitates PRLr degradation. Here, we show that an impaired PRLr turnover results in an augmented PRL signaling and PRL-induced transcription. Human mammary epithelial cells harboring degradation-resistant PRLr display accelerated proliferation and increased invasive growth. Conversely, a decrease in PRLr levels achieved by either pharmacologic or genetic means in human breast cancer cells dramatically reduced transformation and tumorigenic properties of these cells. Consequences of alteration of PRLr turnover for homeostasis of mammary cells and development of breast cancers, as well as the utility of therapies that target PRLr function in these malignancies, are discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19276348      PMCID: PMC2664855          DOI: 10.1158/0008-5472.CAN-08-4033

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study.

Authors:  S Gill; D Peston; B K Vonderhaar; S Shousha
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

Review 3.  Prolactin receptor signal transduction.

Authors:  C V Clevenger; J B Kline
Journal:  Lupus       Date:  2001       Impact factor: 2.911

Review 4.  Cannabimimetic fatty acid derivatives in cancer and inflammation.

Authors:  V Di Marzo; D Melck; L De Petrocellis; T Bisogno
Journal:  Prostaglandins Other Lipid Mediat       Date:  2000-04       Impact factor: 3.072

5.  Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice.

Authors:  H Wennbo; M Gebre-Medhin; A Gritli-Linde; C Ohlsson; O G Isaksson; J Törnell
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

Review 6.  Prolactin as a mitogen in mammary cells.

Authors:  R Das; B K Vonderhaar
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-01       Impact factor: 2.673

7.  Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer.

Authors:  P Lissoni; M Vaghi; A Ardizzoia; E Fumagalli; G Tancini; G Gardani; A Conti; G J Maestroni
Journal:  Neuro Endocrinol Lett       Date:  2001       Impact factor: 0.765

8.  PRL modulates cell cycle regulators in mammary tumor epithelial cells.

Authors:  Matthew D Schroeder; Jaime Symowicz; Linda A Schuler
Journal:  Mol Endocrinol       Date:  2002-01

9.  Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells.

Authors:  D Melck; D Rueda; I Galve-Roperh; L De Petrocellis; M Guzmán; V Di Marzo
Journal:  FEBS Lett       Date:  1999-12-17       Impact factor: 4.124

10.  Prolactin as a local growth promoter in patients with breast cancer: GCRI experience.

Authors:  J M Bhatavdekar; D D Patel; N G Shah; H H Vora; T P Suthar; N Ghosh; P R Chikhlikar; T I Trivedi
Journal:  Eur J Surg Oncol       Date:  2000-09       Impact factor: 4.424

View more
  24 in total

1.  Ubiquitination-dependent regulation of signaling receptors in cancer.

Authors:  Wei-Chun Huangfu; Serge Y Fuchs
Journal:  Genes Cancer       Date:  2010-07

Review 2.  Eliminative signaling by Janus kinases: role in the downregulation of associated receptors.

Authors:  Christopher J Carbone; Serge Y Fuchs
Journal:  J Cell Biochem       Date:  2014-01       Impact factor: 4.429

3.  HMGN2 inducibly binds a novel transactivation domain in nuclear PRLr to coordinate Stat5a-mediated transcription.

Authors:  Alyson A Fiorillo; Terry R Medler; Yvonne B Feeney; Yi Liu; Kalie L Tommerdahl; Charles V Clevenger
Journal:  Mol Endocrinol       Date:  2011-08-04

4.  Growth hormone (GH) receptor (GHR)-specific inhibition of GH-Induced signaling by soluble IGF-1 receptor (sol IGF-1R).

Authors:  Yue Zhang; Sajina Gc; Sweta B Patel; Ying Liu; Andrew J Paterson; John C Kappes; Jing Jiang; Stuart J Frank
Journal:  Mol Cell Endocrinol       Date:  2019-05-14       Impact factor: 4.102

5.  Src tyrosyl phosphorylates cortactin in response to prolactin.

Authors:  Alan Hammer; Sneha Laghate; Maria Diakonova
Journal:  Biochem Biophys Res Commun       Date:  2015-06-01       Impact factor: 3.575

6.  Prolactin inhibits activity of pyruvate kinase M2 to stimulate cell proliferation.

Authors:  Bentley Varghese; Gayathri Swaminathan; Alexander Plotnikov; Christos Tzimas; Ning Yang; Hallgeir Rui; Serge Y Fuchs
Journal:  Mol Endocrinol       Date:  2010-10-20

Review 7.  Tyrosyl phosphorylated serine-threonine kinase PAK1 is a novel regulator of prolactin-dependent breast cancer cell motility and invasion.

Authors:  Alan Hammer; Maria Diakonova
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

8.  The prolactin receptor transactivation domain is associated with steroid hormone receptor expression and malignant progression of breast cancer.

Authors:  Alyson A Fiorillo; Terry R Medler; Yvonne B Feeney; Suzanne M Wetz; Kalie L Tommerdahl; Charles V Clevenger
Journal:  Am J Pathol       Date:  2012-11-14       Impact factor: 4.307

9.  The role of prolactin receptor in GH signaling in breast cancer cells.

Authors:  Jie Xu; Dongmei Sun; Jing Jiang; Luqin Deng; Yue Zhang; Hao Yu; Deepti Bahl; John F Langenheim; Wen Y Chen; Serge Y Fuchs; Stuart J Frank
Journal:  Mol Endocrinol       Date:  2012-11-28

10.  The human intermediate prolactin receptor is a mammary proto-oncogene.

Authors:  Jacqueline M Grible; Patricija Zot; Amy L Olex; Shannon E Hedrick; J Chuck Harrell; Alicia E Woock; Michael O Idowu; Charles V Clevenger
Journal:  NPJ Breast Cancer       Date:  2021-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.